Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain

Current Topics in Behavioral Neurosciences

Volumn 11, Issue , 2011, Pages 169-198

  Hall, Hélène ^a   Cuellar Baena, Sandra ^a   Dahlberg, Carina ^b   Zandt, René In’t ^b   Denisov, Vladimir ^b   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

13C 15N; Alzheimer s disease; Brain; Metabolism; Neurodegeneration; Parkinson s disease

Indexed keywords

4 AMINOBUTYRIC ACID; CREATINE; CREATINE PHOSPHATE; GLUCOSE; INOSITOL; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; PHOSPHORYLCHOLINE; TAURINE; ASPARTIC ACID; ISOTOPE; N-ACETYLASPARTATE; PROTON;

ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; BRAIN FUNCTION; CARBON NUCLEAR MAGNETIC RESONANCE; DEMENTIA; HUMAN; METABOLITE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO; ANALOGS AND DERIVATIVES; BRAIN; DIAGNOSTIC USE; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ASPARTIC ACID; BRAIN; HUMANS; ISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PROTONS;

EID: 84872084552     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2011_166     Document Type: Article

References (155)

1. Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289(1-2): 18-22. doi: S0022-510X(09)00819-3[pii]10. 1016/j. jns. 2009. 08. 034
2. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 384(1-2): 23-28. doi: 10. 1016/j. neulet. 2005. 04. 035
3. Aderinwale OG, Ernst HW, Mousa SA (2010) Current therapies and new strategies for the management of Alzheimer's disease. Am J Alzheimers Dis Other Demen 25(5): 414-424. doi: 10. 1177/1533317510372372
4. Allouche-Arnon H, Gamliel A, Barzilay CM, Nalbandian R, Gomori JM, Karlsson M, Lerche MH, Katz-Brull R (2010) A hyperpolarized choline molecular probe for monitoring acetylcholine synthesis. Contrast Media Mol Imaging. doi: 10. 1002/cmmi. 418
5. Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43: 388-393
6. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K (2003) Increase in signal-to-noise ratio of[10, 000 times in liquidstate NMR. Proc Natl Acad Sci U S A 100(18): 10158-10163. doi: 10. 1073/pnas. 17338351 001733835100[pii]
7. Azevedo D, Tatsch M, Hototian SR, Bazzarella MC, Castro CC, Bottino CM (2008) Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a communitybased study. Dement Geriatr Cogn Disord 25(6): 491-500. doi: 10. 1159/000128275
8. Bartha R, Drost DJ, Williamson PC (1999) Factors affecting the quantification of short echo in vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed 12(4): 205-216
9. Baslow MH (2003) N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 28(6): 941-953
10. Beckmann N, Turkalj I, Seelig J, Keller U (1991) 13C NMR for the assessment of human brain glucose metabolism in vivo. Biochem 30(26): 6362-6366
11. Beckmann N, Hof RP, Rudin M (2000) The role of magnetic resonance imaging and spectroscopy in transplantation: from animal models to man. NMR Biomed 13(6): 329-348. doi: 10. 1002/1099-1492(200010)13: 6\329: AID-NBM653[3. 0. CO; 2-W[pii]
12. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R (2007) GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 87(4): 1215-1284. doi: 87/4/1215[pii]10. 1152/physrev. 00017. 2006
13. Bondareff W, Mountjoy CQ, Roth M (1981) Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1: 783-784
14. Bosboom JL, Stoffers D, Wolters E (2004) Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111(10-11): 1303-1315. doi: 10. 1007/s00702-004-0168-1
15. Brief EE, Moll R, Li DK, Mackay AL (2009) Absolute metabolite concentrations calibrated using the total water signal in brain (1) H MRS. NMRBiomed 22(3): 349-354. doi: 10. 1002/nbm. 1349
16. Brooks DJ (2003) PET studies on the function of dopamine in health and Parkinson's disease. Ann N Y Acad Sci 991: 22-35
17. Callaghan P (1991) Principles of nuclear magnetic resonance spectroscopy. Oxford University Press, New York
18. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D (2001) Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 14(4): 278-283
19. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y (2004) Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003(1-2): 26-35. doi: 10. 1016/j. brainres. 2003. 11. 074
20. Chaumeil MM, Valette J, Guillermier M, Brouillet E, Boumezbeur F, Herard AS, Bloch G, Hantraye P, Lebon V (2009) Multimodal neuroimaging provides a highly consistent picture of energy metabolism, validating 31P MRS for measuring brain ATP synthesis. Proc Nat Acad Sci U S A 106 (10): 3988-3993. doi: 10. 1073/pnas. 0806516106
21. Choe BY, Park JW, Lee KS, Son BC, Kim MC, Kim BS, Suh TS, Lee HK, Shinn KS (1998) Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 33(8): 450-455
22. Choi IY, Tkac I, Ugurbil K, Gruetter R (1999) Noninvasive measurements of [1-(13)C]glycogen concentrations and metabolism in rat brain in vivo. J Neurochem 73(3): 1300-1308
23. Choi JK, Dedeoglu A, Jenkins BG (2007) Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 20(3): 216-237. doi: 10. 1002/nbm. 1145
24. Clark JB (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20(4-5): 271-276. doi: dne20271[pii]
25. Clarke CE, Lowry M (2000) Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 7(6): 661-665. doi: ene111[pii]
26. Clarke CE, Lowry M (2001) Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol Soc 8(6): 573-577
27. Cooper J, Bloom F, Roth R (2003) The biochemical basis of neuropharmacology, 8th edn. Oxford University Press, Inc, New York
28. Cowan CM, Raymond LA (2006) Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 75: 25-71. doi: S0070-2153(06)75002-5[pii]10. 1016/S0070-2153(06)75002-5
29. Cox IJ (1996) Development and applications of in vivo clinical magnetic resonance spectroscopy. Prog Biophys Mol Biol 65(1-2): 45-81. doi: S0079-6107(96)00006-5[pii]
30. Cudalbu C, Comment A, Kurdzesau F, van Heeswijk RB, Uffmann K, Jannin S, Denisov V, Kirik D, Gruetter R (2010) Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Phys Chem Chem Phys 12(22): 5818-5823. doi: 10. 1039/c002309b
31. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM (2007) Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 13(11): 1382-1387. doi: 10. 1038/nm1650
32. de Graaf RA (2007) In vivo NMR spectroscopy, 2nd edn. Wiley, Chicester
33. de Graaf AA, Bovee WM (1990) Improved quantification of in vivo 1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting. Magn Reson Med 15(2): 305-319
34. de Graaf RA, Mason GF, Patel AB, Behar KL, Rothman DL (2003) In vivo 1H-[13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed 16(6-7): 339-357. doi: 10. 1002/nbm. 847
35. Di Costanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M, Bonavita S, Tedeschi G, Scarabino T (2003) High-field proton MRS of human brain. Eur J Radiol 48(2): 146-153. doi: 10. 1016/j. ejrad. 2003. 08. 009S0720048X03002420[pii]
36. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD (2002) Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain J Neurol 125(Pt 10): 2332-2341
37. Doraiswamy PM, Charles HC, Krishnan KR (1998) Prediction of cognitive decline in early Alzheimer's disease. Lancet 352(9141): 1678. doi: 10. 1016/S0140-6736(05)61449-3
38. Du F, Zhu XH, Qiao H, Zhang X, Chen W (2007) Efficient in vivo 31P magnetization transfer approach for noninvasively determining multiple kinetic parameters and metabolic fluxes of ATPmetabolism in the human brain. Magn Reson Med57(1): 103-114. doi: 10. 1002/mrm. 21107
39. Edden RA, Harris AD, Murphy K, Evans CJ, Saxena N, Hall JE, Bailey DM, Wise RG (2010) Edited MRS is sensitive to changes in lactate concentration during inspiratory hypoxia. J Magn Reson Imaging 32(2): 320-325. doi: 10. 1002/jmri. 22233
40. Ellis CM, Lemmens G, Williams SC, Simmons A, Dawson J, Leigh PN, Chaudhuri KR (1997) Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 49(2): 438-444
41. Farlow MR, Cummings J (2008) A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 25(4): 301-308. doi: 10. 1159/000119104
42. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain J Neurol 114(Pt 5): 2283-2301
43. Firbank MJ, Harrison RM, O'Brien JT (2002) A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 14(2): 64-76
44. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198
45. Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. J Neurochem 42(1): 1-11
46. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66(2): 137-147
47. Frederick BD, Lyoo IK, Satlin A, Ahn KH, Kim MJ, Yurgelun-Todd DA, Cohen BM, Renshaw PF (2004) In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 28(8): 1313-1322. doi: 10. 1016/j. pnpbp. 2004. 08. 013
48. Fumita M, Innis RB (2002) In vivo molecular imaging: ligand development and research applications. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology-the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia
49. Gabellieri C, Reynolds S, Lavie A, Payne GS, Leach MO, Eykyn TR (2008) Therapeutic target metabolism observed using hyperpolarized 15N choline. J Am Chem Soc 130(14): 4598-4599. doi: 10. 1021/ja8001293
50. Gadian D (1995) NMR and its applications to living systems, 2nd edn. Oxford university press, Oxford
51. Galanaud D, Nicoli F, Confort-Gouny S, Le Fur Y, Dormont D, Girard N, Ranjeva J, Cozzone P (2007) [Brain magnetic resonance spectroscopy]. J Radiol 88(3 Pt 2): 483-496. doi: MDOI-JR-03-2007-88-3-C2-0221-0363-101019-200700145 [pii]
52. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM (2008) Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453(7197): 940-943. doi: 10. 1038/nature07017
53. Garcia Santos JM, Gavrila D, Antunez C, Tormo MJ, Salmeron D, Carles R, Jimenez Veiga J, Parrilla G, Torres del Rio S, Fortuna L, Navarro C (2008) Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. Dement Geriatr Cogn Disord 26(1): 15-25. doi: 10. 1159/000140624
54. Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, Brugieres P, Mangin JF, Boisse MF, Palfi S, Cesaro P, Samson Y, Hantraye P, Peschanski M, Remy P (2004) Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain J Neurol 127(Pt 1): 65-72. doi: 10. 1093/brain/awh003
55. Golman K, Olsson LE, Axelsson O, Mansson S, Karlsson M, Petersson JS (2003) Molecular imaging using hyperpolarized 13C. Br J Radiol 76 Spec No 2: S118-127
56. Golman K, in'tZandt R, Thaning M (2006a) Real-time metabolic imaging. Proc Natl Acad Sci U S A 103(30): 11270-11275. doi: 0601319103[pii]10. 1073/pnas. 0601319103
57. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH (2006b) Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66(22): 10855-10860. doi: 66/22/10855[pii]10. 1158/0008-5472. CAN-06-2564
58. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Mansson S (2008) Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med 59(5): 1005-1013. doi: 10. 1002/mrm. 21460
59. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC (2008) Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 4(6): 421-427. doi: S1552-5260(08)00128-3[pii]10. 1016/j. jalz. 2008. 04. 008
60. Griffith HR, Stewart CC, den Hollander JA (2009) Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. Int Rev Neurobiol 84: 105-131. doi: S0074-7742(09) 00406-1[pii]10. 1016/S0074-7742(09)00406-1
61. Gruber S, Mlynarik V, Moser E (2003) High-resolution 3D proton spectroscopic imaging of the human brain at 3 T: SNR issues and application for anatomy-matched voxel sizes. Magn Reson Med 49: 299-306
62. Gruetter R, Magnusson I, Rothman DL, Avison MJ, Shulman RG, Shulman GI (1994) Validation of 13C NMR measurements of liver glycogen in vivo. Magn Reson Med 31(6): 583-588
63. Gruetter R, Weisdorf SA, Rajanayagan V, Terpstra M, Merkle H, Truwit CL, Garwood M, Nyberg SL, Ugurbil K (1998) Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson 135(1): 260-264. doi: S1090-7807(98)91542-7[pii]10. 1006/jmre. 1998. 1542
64. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le Goff L, Salin P (2006) Chronic highfrequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 24(6): 1802-1814. doi: EJN5047[pii]10. 1111/j. 1460-9568. 2006. 05047. x
65. Harris T, Giraudeau P, Frydman L (2010) Kinetics from indirectly detected hyperpolarized NMR spectroscopy by using spatially selective coherence transfers. Chemistry. doi: 10. 1002/chem. 201002151
66. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132(Pt 12): 3285-3297. doi: awp293[pii]10. 1093/brain/awp293
67. Henchcliffe C, Shungu DC, Mao X, Huang C, Nirenberg MJ, Jenkins BG, Beal MF (2008) Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci 1147: 206-220. doi: NYAS1147037[-pii]10. 1196/annals. 1427. 037
68. Herholz K, Carter SF, Jones M (2007) Positron emission tomography imaging in dementia. Br J Radiol 80 Spec No 2: S160-167. doi: 80/Special_Issue_2/S160 [pii] 10. 1259/bjr/97295129
69. Hetherington HP, Pan JW, Spencer DD (2002) 1H and 31P spectroscopy and bioenergetics in the lateralization of seizures in temporal lobe epilepsy. J Magn Reson Imaging 16(4): 477-483. doi: 10. 1002/jmri. 10177
70. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180): 345-348. doi: 10. 1038/334345a0
71. Hoogendijk WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W, Eikelenboom P, Swaab DF (1999) Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 45: 82-91
72. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572
73. Hutchinson PJ, O'Connell MT, Kirkpatrick PJ, Pickard JD (2002) How can we measure substrate, metabolite and neurotransmitter concentrations in the human brain? Physiol Meas 23(2): R75-109
74. Hyder F (2009) Dynamic imaging of brain function. Methods Mol Biol 489: 3-21. doi: 10. 1007/978-1-59745-543-5_1
75. Jenkins BG, Chen YI, Kuestermann E, Makris NM, Nguyen TV, Kraft E, Brownell AL, Rosas HD, Kennedy DN, Rosen BR, Koroshetz WJ, Beal MF (1999) An integrated strategy for evaluation of metabolic and oxidative defects in neurodegenerative illness using magnetic resonance techniques. Ann N Y Acad Sci 893: 214-242
76. Jessen F, Traeber F, Freymann N, Maier W, Schild H, Heun R, Block W (2005) A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease. Dement Geriatr Cogn Disord 20(2-3): 178-183
77. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W (2006) Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67(3): 528-530. doi: 10. 1212/01. wnl. 0000228218. 68451. 31
78. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr (2004) 1H MR spectroscopy in common dementias. Neurology 63(8): 1393-1398. doi: 63/8/1393[pii]
79. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28(9): 1330-1339. doi: 10. 1016/j. neurobiolaging. 2006. 06. 018
80. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR Jr (2008) Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248(1): 210-220. doi: 248/1/210[pii]10. 1148/radiol. 2481071590
81. Katz-Brull R, Koudinov AR, Degani H (2005) Direct detection of brain acetylcholine synthesis by magnetic resonance spectroscopy. Brain Res 1048(1-2): 202-210. doi: S0006-8993(05)00684-0[pii]10. 1016/j. brainres. 2005. 04. 080
82. Kauppinen RA, Williams SR (1994) Nuclear magnetic resonance spectroscopy studies of the brain. Prog Neurobiol 44(1): 87-118. doi: 0301-0082(94)90058-2[pii]
83. Keeler J (2005) Understanding NMR spectroscopy. 1st edn, Wiley, Chicester
84. Kirik D, Breysse N, Bjorklund T, Besret L, Hantraye P (2005) Imaging in cell-based therapy for neurodegenerative diseases. Eur J Nucl Med Mol Imaging 32 Suppl 2: S417-434. doi: 10. 1007/s00259-005-1909-6
85. Klomp DW, Renema WK, van der Graaf M, de Galan BE, Kentgens AP, Heerschap A (2006) Sensitivity-enhanced 13C MR spectroscopy of the human brain at 3 Tesla. Magn Reson Med 55(2): 271-278. doi: 10. 1002/mrm. 20745
86. Klomp DW, Wijnen JP, Scheenen TW, Heerschap A (2008) Efficient 1H to 31P polarization transfer on a clinical 3T MR system. Magn Reson Med 60(6): 1298-1305. doi: 10. 1002/mrm. 21733
87. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Nat Acad Sci U S A 83(11): 4044-4048
88. Kreis R, Ernst HW, Ross BD (1993) absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations J Magn Reson-Series B 102: 9-19
89. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160(11): 2003-2011
90. Kulak A, Duarte JM, Do KQ, Gruetter R (2010) Neurochemical profile of the developing mouse cortex determined by in vivo 1H NMR spectroscopy at 14. 1 T and the effect of recurrent anaesthesia. J Neurochem 115(6): 1466-1477. doi: 10. 1111/j. 1471-4159. 2010. 07051. x
91. Lei H, Poitry-Yamate C, Preitner F, Thorens B, Gruetter R (2010) Neurochemical profile of the mouse hypothalamus using in vivo 1H MRS at 14. 1 T. NMR Biomed 23(6): 578-583. doi: 10. 1002/nbm. 1498
92. Lien YH, Shapiro JI, Chan L (1990) Effects of hypernatremia on organic brain osmoles. J Clin Invest 85(5): 1427-1435. doi: 10. 1172/JCI114587
93. Lin A, Ross BD, Harris K, Wong W (2005) Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2(2): 197-214
94. Lucetti C, Del Dotto P, Gambaccini G, Ceravolo R, Logi C, Berti C, Rossi G, Bianchi MC, Tosetti M, Murri L, Bonuccelli U (2007) Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord 22(15): 2170-2175. doi: 10. 1002/mds. 21576
95. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, Fein G, Weiner MW (1996) Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198(2): 537-545
96. Mansson S, Johansson E, Magnusson P, Chai CM, Hansson G, Petersson JS, Stahlberg F, Golman K (2006) 13C imaging-a new diagnostic platform. Eur Radiol 16(1): 57-67. doi: 10. 1007/s00330-005-2806-x
97. Marson DC, Dymek MP, Duke LW, Harrell LE (1997) Subscale validity of the Mattis Dementia Rating Scale. Arch Clin Neuropsychol 12(3): 269-275
98. Martin WR (2007) MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 9(4): 196-203. doi: 10. 1007/s11307-007-0087-2
99. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40(5): 759-766. doi: 10. 1002/ana. 410400512
100. Mierisova S, Ala-Korpela M (2001) MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed 14(4): 247-259
101. Mlynarik V, Cudalbu C, Xin L, Gruetter R (2008a) 1H NMR spectroscopy of rat brain in vivo at 14. 1Tesla: improvements in quantification of the neurochemical profile. J Magn Reson 194 (2): 163-168. doi: S1090-7807(08)00205-X [pii] 10. 1016/j. jmr. 2008. 06. 019
102. Mlynarik V, Kohler I, Gambarota G, Vaslin A, Clarke PG, Gruetter R (2008b) Quantitative proton spectroscopic imaging of the neurochemical profile in rat brain with microliter resolution at ultra-short echo times. Magn Reson Med 59(1): 52-58. doi: 10. 1002/mrm. 21447
103. Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162(4): 667-675. doi: 10. 1176/appi. ajp. 162. 4. 667
104. Modrego PJ, Pina MA, Fayed N, Diaz M (2006) Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20(10): 867-877
105. Mohanakrishnan P, Fowler AH, Vonsattel JP, Husain MM, Jolles PR, Liem P, Komoroski RA (1995) An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 102(3): 503-510
106. Moreno A, Ross BD, Bluml S (2001) Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem 77(1): 347-350
107. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Archives of neurology 58(3): 397-405
108. Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119(Pt 2): 585-591
109. Nakano I, Hirano A (1984) Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 15(5): 415-418. doi: 10. 1002/ana. 410150503
110. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D (2001) Java-based graphical user interface for the MRUI quantitation package. Magma 12(2-3): 141-152
111. Novotny EJ, Jr., Fulbright RK, Pearl PL, Gibson KM, Rothman DL (2003) Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol 54 Suppl 6: S25-31. doi: 10. 1002/ana. 10697
112. Nyberg P, Nordberg A, Wester P, Winblad B (1983) Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem Pathology 1(3): 193-202. doi: 10. 1007/BF02834244
113. Olanow CW, Kordower JH, Freeman TB (1996) Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19(3): 102-109
114. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW (2002) Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 17(5): 917-927. doi: 10. 1002/mds. 10214
115. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115(Pt 6): 1727-1751
116. Oz G, Terpstra M, Tkac I, Aia P, Lowary J, Tuite PJ, Gruetter R (2006) Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 55(2): 296-301. doi: 10. 1002/mrm. 20761
117. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48(5): 413-421
118. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3): 303-308
119. Pfeilsticker JA, Ollerenshaw JE, Norton VA, Weitekamp DP (2010) A selective 15N-to-(1)H polarization transfer sequence for more sensitive detection of 15N-choline. J Magn Reson 205(1): 125-129. doi: S1090-7807(10)00112-6[pii]10. 1016/j. jmr. 2010. 04. 010
120. Pfeuffer J, Tkac I, Provencher SW, Gruetter R (1999) Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 141(1): 104-120. doi: 10. 1006/jmre. 1999. 1895S1090-7807(99)91895-5[pii]
121. Prichard J, Rothman D, Novotny E, Petroff O, Kuwabara T, Avison M, Howseman A, Hanstock C, Shulman R (1991) Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA 88(13): 5829-5831
122. Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LC Model. NMR biomed 14(4): 260-264
123. Przedborski S, Vila M, Jackson-Lewis V (2003) Neurodegeneration: what is it and where are we? J Clin Invest 111(1): 3-10. doi: 10. 1172/JCI17522
124. Qiao H, Zhang X, Zhu XH, Du F, Chen W (2006) In vivo 31P MRS of human brain at high/ultrahigh fields: a quantitative comparison of NMR detection sensitivity and spectral resolution between 4 T and 7 T. Magn Reson Imaging 24(10): 1281-1286. doi: 10. 1016/j. mri. 2006. 08. 002
125. Radda GK (1986) The use of NMR spectroscopy for the understanding of disease. Science 233(4764): 640-645
126. Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P (2008) Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol, Neurosurg, Psychiatry 79(8): 948-951. doi: 10. 1136/jnnp. 2007. 142380
127. Rosen Y, Lenkinski RE (2007) Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 4(3): 330-345. doi: S1933-7213(07)00082-7[pii]10. 1016/j. nurt. 2007. 04. 009
128. Ross B, Bluml S (2001) Magnetic resonance spectroscopy of the human brain. Anat Rec 265(2): 54-84. doi: 10. 1002/ar. 1058[pii]
129. Ross BD, Hoang TQ, Bluml S, Dubowitz D, Kopyov OV, Jacques DB, Lin A, Seymour K, Tan J (1999) In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 12(4): 221-236. doi: 10. 1002/(SICI)1099-1492(199906)12: 4\221: AID-NBM582[3. 0. CO; 2-Q[pii]
130. Ross BD, Bhattacharya P, Wagner S, Tran T, Sailasuta N (2010) Hyperpolarized MR imaging: neurologic applications of hyperpolarized metabolism. AJNR Am J Neuroradiol 31(1): 24-33. doi: ajnr. A1790[pii]10. 3174/ajnr. A1790
131. Sarkar R, Comment A, Vasos PR, Jannin S, Gruetter R, Bodenhausen G, Hall H, Kirik D, Denisov VP (2009) Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization. J Am Chem Soc 131(44): 16014-16015. doi: 10. 1021/ja9021304
132. Sawle GV, Myers R (1993) The role of positron emission tomography in the assessment of human neurotransplantation. Trends Neurosci 16(5): 172-176
133. Schaeffter T, Dahnke H (2008) Magnetic resonance imaging and spectroscopy. Handb Exp Pharmacol (185 Pt 1): 75-90. doi: 10. 1007/978-3-540-72718-7_4
134. Schott JM, Frost C, MacManus DG, Ibrahim F, Waldman AD, Fox NC (2010) Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain J Neurol 133(11): 3315-3322. doi: 10. 1093/brain/awq208
135. Schulz UG, Blamire AM, Davies P, Styles P, Rothwell PM (2009) Normal cortical energy metabolism in migrainous stroke: A 31P-MR spectroscopy study. Stroke J cereb circ 40(12): 3740-3744. doi: 10. 1161/STROKEAHA. 109. 558163
136. Shinno H, Inagaki T, Miyaoka T, Okazaki S, Kawamukai T, Utani E, Inami Y, Horiguchi J (2007) A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci 260(1-2): 132-138. doi: 10. 1016/j. jns. 2007. 04. 017
137. Shulman RG, Rothman DL, Behar KL, Hyder F (2004) Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 27(8): 489-495. doi: 10. 1016/j. tins. 2004. 06. 005
138. Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman RG (1997) In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. Proc Natl Acad Sci U S A 94(6): 2699-2704
139. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A 95(1): 316-321
140. Stanley JA, Drost DJ, Williamson PC, Thompson RT (1995) The use of a priori knowledge to quantify short echo in vivo 1H MR spectra. Magn Reson Med 34(1): 17-24
141. Stockler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, Hanicke W, Frahm J (1994) Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 36(3): 409-413
142. Strome EM, Doudet DJ (2007) Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol 9(4): 186-195. doi: 10. 1007/s11307-007-0093-4
143. Summerfield C, Gomez-Anson B, Tolosa E, Mercader JM, Marti MJ, Pastor P, Junque C (2002) Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 59(9): 1415-1420. doi: noc10313[pii]
144. Svensson J, Mansson S, Johansson E, Petersson JS, Olsson LE (2003) Hyperpolarized 13C MR angiography using true FISP. Magn Reson Med 50(2): 256-262. doi: 10. 1002/mrm. 10530
145. Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R (2001) In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 46(3): 451-456. doi: 10. 1002/mrm. 1213[pii]
146. Ugurbil K, Brown TR, den Hollander JA, Glynn P, Shulman RG (1978) High-resolution 13C nuclear magnetic resonance studies of glucose metabolism in Escherichia coli. Proc Natl Acad Sci U S A 75(8): 3742-3746
147. Ugurbil K, Adriany G, Andersen P, Chen W, Gruetter R, Hu X, Merkle H, Kim DS, Kim SG, Strupp J, Zhu XH, Ogawa S (2000) Magnetic resonance studies of brain function and neurochemistry. Annu Rev Biomed Eng 2: 633-660. doi: 2/1/633[pii]10. 1146/annurev. bioeng. 2. 1. 633
148. Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13(3): 981-989
149. Vandersprenkel JWB, Luyten PR, Vanrijen PC, Tulleken CAF, Denhollander JA (1988) Cerebral lactate detected by regional proton magnetic-resonance spectroscopy in a patient with cerebral infarction. Stroke 19(12): 1556-1560
150. Vanhamme L, Sundin T, Hecke PV, Huffel SV (2001) MR spectroscopy quantitation: a review of time-domain methods. NMR Biomed 14(4): 233-246
151. Waldman AD, Rai GS (2003) The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiol 45(8): 507-512. doi: 10. 1007/s00234-003-1040-y
152. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215(4537): 1237-1239
153. Wijnen JP, Scheenen TW, Klomp DW, Heerschap A (2010) 31P magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono-and diesters at 3 T in the human brain: relation with age and spatial differences. NMR Biomed 23(8): 968-976. doi: 10. 1002/nbm. 1523
154. Yang H, Tang X, Tan L, Zeng L, Hu Z (2008) Use of 31P magnetic resonance spectroscopy to study the effect of cortical magnesium and energy metabolism after subarachnoid hemorrhage. Cerebrovasc Dis 26(3): 223-230. doi: 10. 1159/000147448
155. Zhu XH, Du F, Zhang N, Zhang Y, Lei H, Zhang X, Qiao H, Ugurbil K, Chen W (2009) Advanced in vivo heteronuclear MRS approaches for studying brain bioenergetics driven by mitochondria. Methods Mol Biol 489: 317-357. doi: 10. 1007/978-1-59745-543-5_15